

# The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis



Stéphanie Roberge, PhD; Kypros Nicolaidis, MD; Suzanne Demers, MD, MSc; Jon Hyett, MD; Nils Chaillet, PhD; Emmanuel Bujold, MD, MSc

**BACKGROUND:** Preeclampsia and fetal growth restriction are major causes of perinatal death and handicap in survivors. Randomized clinical trials have reported that the risk of preeclampsia, severe preeclampsia, and fetal growth restriction can be reduced by the prophylactic use of aspirin in high-risk women, but the appropriate dose of the drug to achieve this objective is not certain.

**OBJECTIVE:** We sought to estimate the impact of aspirin dosage on the prevention of preeclampsia, severe preeclampsia, and fetal growth restriction.

**STUDY DESIGN:** We performed a systematic review and meta-analysis of randomized controlled trials comparing the effect of daily aspirin or placebo (or no treatment) during pregnancy. We searched MEDLINE, Embase, Web of Science, and Cochrane Central Register of Controlled Trials up to December 2015, and study bibliographies were reviewed. Authors were contacted to obtain additional data when needed. Relative risks for preeclampsia, severe preeclampsia, and fetal growth restriction were calculated with 95% confidence intervals using random-effect models. Dose-response effect was evaluated using meta-regression and reported as adjusted  $R^2$ . Analyses were stratified according to gestational age at initiation of aspirin ( $\leq 16$  and  $>16$  weeks) and repeated after exclusion of studies at high risk of biases.

**RESULTS:** In all, 45 randomized controlled trials included a total of 20,909 pregnant women randomized to between 50–150 mg of aspirin daily. When aspirin was initiated at  $\leq 16$  weeks, there was a significant reduction and a dose-response effect for the prevention of preeclampsia (relative risk, 0.57; 95% confidence interval, 0.43–0.75;  $P < .001$ ;  $R^2$ , 44%;  $P = .036$ ), severe preeclampsia (relative risk, 0.47; 95% confidence interval, 0.26–0.83;  $P = .009$ ;  $R^2$ , 100%;  $P = .008$ ), and fetal growth restriction (relative risk, 0.56; 95% confidence interval, 0.44–0.70;  $P < .001$ ;  $R^2$ , 100%;  $P = .044$ ) with higher dosages of aspirin being associated with greater reduction of the 3 outcomes. Similar results were observed after the exclusion of studies at high risk of biases. When aspirin was initiated at  $>16$  weeks, there was a smaller reduction of preeclampsia (relative risk, 0.81; 95% confidence interval, 0.66–0.99;  $P = .04$ ) without relationship with aspirin dosage ( $R^2$ , 0%;  $P = .941$ ). Aspirin initiated at  $>16$  weeks was not associated with a risk reduction or a dose-response effect for severe preeclampsia (relative risk, 0.85; 95% confidence interval, 0.64–1.14;  $P = .28$ ;  $R^2$ , 0%;  $P = .838$ ) and fetal growth restriction (relative risk, 0.95; 95% confidence interval, 0.86–1.05;  $P = .34$ ;  $R^2$ , not available;  $P = .563$ ).

**CONCLUSION:** Prevention of preeclampsia and fetal growth restriction using aspirin in early pregnancy is associated with a dose-response effect. Low-dose aspirin initiated at  $>16$  weeks' gestation has a modest or no impact on the risk of preeclampsia, severe preeclampsia, and fetal growth restriction. Women at high risk for those outcomes should be identified in early pregnancy.

**Key words:** aspirin, fetal growth restriction, meta-analysis, meta-regression, preeclampsia, pregnancy, systematic review

From the Department of Obstetrics and Gynecology, Faculty of Medicine, Université Laval, Quebec City, Quebec, Canada (Drs Roberge, Demers, Chaillet, and Bujold); Harris Birthright Research Center of Fetal Medicine, King's College Hospital, London, United Kingdom (Drs Roberge, Nicolaidis, and Demers); and Department of Obstetrics and Gynecology, Faculty of Medicine, Central Clinical, University of Sydney, Sydney, Australia (Dr Hyett).

Received July 18, 2016; revised Aug. 25, 2016; accepted Sept. 7, 2016.

The Canadian Institute of Health Research supported Dr Roberge (postdoctoral fellowship). The Fond de Recherche du Québec—Santé supported Dr Bujold (clinician scientist award) and Dr Demers (MSc award) during the study. The study was funded by the Jeanne and Jean-Louis Lévesque Perinatal Research Chair at Université Laval.

The authors report no conflict of interest.

Presented as an oral presentation at the 14th World Congress in Fetal Medicine, Crete, Greece, June 23, 2015.

Corresponding author: Emmanuel Bujold, MD, MSc. [emmanuel.bujold@crchudequebec.ulaval.ca](mailto:emmanuel.bujold@crchudequebec.ulaval.ca)

0002-9378/\$36.00 • © 2016 Elsevier Inc. All rights reserved. • <http://dx.doi.org/10.1016/j.ajog.2016.09.076>

➤ Related editorial, page 95.




Click Supplemental Materials  
under article title in Contents at [ajog.org](http://ajog.org)

## Introduction

Preeclampsia (PE) and fetal growth restriction (FGR) are important causes of perinatal death and handicap in survivors. PE is responsible for >70,000 maternal deaths each year around the world.<sup>1</sup> Additionally, PE is associated with increased long-term risk for development of cardiovascular disease in both the mother and her infant.<sup>2-4</sup>

Several studies examined the possibility that prophylactic use of low-dose aspirin in women at high risk of developing PE could reduce the prevalence of the disease. Meta-analyses of randomized controlled trials (RCTs) of aspirin vs placebo or no treatment showed that the prevalence of PE and FGR can be reduced by aspirin started at  $\leq 16$  weeks' gestation and the effect is most marked for severe PE leading to delivery at <34 weeks' gestation; aspirin started at >16 weeks had no significant effect on the prevalence of severe PE or FGR.<sup>5,6</sup>

**FIGURE 1**  
Study selection process



Selection tree for selection of included articles.

Roberge. Aspirin's dose for prevention of preeclampsia. *Am J Obstet Gynecol* 2017.

**TABLE 1**  
Characteristics of included studies according to gestational age at initiation of intervention

Study	N	Inclusion criteria	Intervention		
			Aspirin	Controls	Onset, wk
$\leq 16$ wk			Aspirin	Controls	Onset, wk
Tulppala et al, <sup>63</sup> 1997	66	Previous consecutive miscarriage	50 mg	Placebo	<7
Benigni et al, <sup>32</sup> 1989	33	History risk factors <sup>a</sup>	60 mg	Placebo	12
<sup>b</sup> Caritis et al, <sup>34</sup> 1998	652	History risk factor <sup>a</sup>	60 mg	Placebo	13–16
<sup>b</sup> Sibai et al, <sup>60</sup> 1993	644	Nulliparity	60 mg	Placebo	13–16
<sup>b</sup> Golding, <sup>41</sup> 1998	1997	Nulliparity	60 mg	Placebo	12–16
<sup>b</sup> Ebrashy et al, <sup>38</sup> 2005	136	Abnormal uterine artery Doppler plus history risk factors <sup>a</sup>	75 mg	No treatment	14–16
Zhao et al, <sup>69</sup> 2012	237	History risk factor <sup>a</sup>	75 mg	Placebo	13–16
Odibo et al, <sup>54</sup> 2015	30	History risk factor <sup>a</sup>	80 mg	Placebo	11–13
Porreco et al, <sup>56</sup> 1993	90	Nulliparity + multiple gestation	80 mg	Placebo	<16
Jamal et al, <sup>46</sup> 2012	70	Diagnose PCOS before pregnancy, 18–40 y, singleton, no history of diabetes or HTN	80 mg	No treatment	6–12
Mesdaghinia et al, <sup>50</sup> 2011	80	Abnormal uterine artery Doppler	80 mg	No treatment	12–16
August et al, <sup>26</sup> 1994	54	History risk factors <sup>a</sup>	100 mg	Placebo	13–15
Azar and Turpin, <sup>28</sup> 1990	91	History risk factors <sup>a</sup>	100 mg <sup>c</sup>	No treatment	16
Bakhti and Vaiman, <sup>29</sup> 2011	84	Nulliparity	100 mg	No treatment	8–10
Chiapparino et al, <sup>35</sup> 2004	35	Chronic HTN with or without history risk factors <sup>a</sup>	100 mg	No treatment	<14
Dasari et al, <sup>36</sup> 1998	50	Nulliparity	100 mg	Placebo	12
Hermida et al, <sup>45</sup> 1997	107	History risk factors <sup>a</sup>	100 mg	Placebo	12–16

Roberge. Aspirin's dose for prevention of preeclampsia. *Am J Obstet Gynecol* 2017.

(continued)

**TABLE 1**  
**Characteristics of included studies according to gestational age at initiation of intervention** (continued)

Study	N	Inclusion criteria	Intervention		
Ayala et al, <sup>27</sup> 2013	350	History risk factors <sup>a</sup>	100 mg	Placebo	12–16
Michael et al, <sup>51</sup> 1992	110	HTN with history risk factors <sup>a</sup>	100 mg	Placebo	<16
<sup>b</sup> Villa et al, <sup>64</sup> 2013	121	Abnormal uterine artery Doppler and history risk factors <sup>a</sup>	100 mg	Placebo	13–14
Beaufils et al, <sup>31</sup> 1985	93	History risk factors <sup>a</sup>	150 mg <sup>c</sup>	No treatment	14
<b>&gt;16 wk</b>					
Zimmermann et al, <sup>70</sup> 1997	26	Abnormal uterine artery Doppler	50 mg	No treatment	22–24
<sup>b</sup> Caritis et al, <sup>34</sup> 1998	1851	History risk factor <sup>a</sup>	60 mg	Placebo	17–26
CLASP, <sup>24</sup> 1994	2492	History risk factors <sup>a</sup>	60 mg	Placebo	20–32
ECPA, <sup>25</sup> 1996	606	History risk factors <sup>a</sup>	60 mg	Placebo	20–32
Ferrier et al, <sup>39</sup> 1996	43	Nulliparity with abnormal umbilical artery Doppler	60 mg	Placebo	22–24
<sup>b</sup> Golding, <sup>41</sup> 1998	4292	Nulliparity	60 mg	Placebo	20–32
Hauth et al, <sup>43</sup> 1993	606	Nulliparity	60 mg	Placebo	24
<sup>b</sup> Sibai et al, <sup>60</sup> 1993	2340	Nulliparity	60 mg	Placebo	17–25
Kim et al, <sup>47</sup> 1997	70	History risk factors <sup>a</sup>	60 mg	No treatment	20–24
Wallenburg et al, <sup>66</sup> 1986	46	Nulliparity with positive angiotensin II sensitivity test	60 mg	Placebo	28
Wallenburg et al, <sup>65</sup> 1991	36	Nulliparity with positive angiotensin II sensitivity test	60 mg	Placebo	28–34
Byaruhanga et al, <sup>33</sup> 1998	230	History of PE, or chronic HTN	75 mg	Placebo	20–28
Davies et al, <sup>37</sup> 1995	118	Nulliparity	75 mg	Placebo	18
McParland et al, <sup>49</sup> 1990	100	Nulliparity with abnormal uterine artery Doppler	75 mg	Placebo	24
Rotchell et al, <sup>57</sup> 1998	1485	All pregnant women	75 mg	Placebo	20–32
Wang and Li, <sup>67</sup> 1996	84	History risk factors <sup>a</sup>	75 mg	Placebo	28–34
Rogers 1999 <sup>106</sup>	193	Normotensive, primigravid with MAP $\geq$ 80 mm Hg and <106 mm Hg early in second trimester and MAP >60 mm Hg	80 mg	Unclear	22
Schrocksadel et al, <sup>59</sup> 1992	41	Nulliparity with positive roll-over test	80 mg	Placebo	28–32
Grab et al, <sup>42</sup> 2000	43	Singleton with history risk factor	100 mg	Placebo	20
Omran et al, <sup>55</sup> 1992	40	History risk factors <sup>a</sup> with positive roll-over test	100 mg	Placebo	28–30
Gallery et al, <sup>40</sup> 1997	120	History risk factors <sup>a</sup>	100 mg	Placebo	17–19
McCowan et al, <sup>48</sup> 1999	99	FGR with abnormal umbilical artery Doppler	100 mg	Placebo	24–36
Morris et al, <sup>52</sup> 1996	102	Nulliparity with abnormal umbilical artery Doppler	100 mg	Placebo	17–19
Newnham et al, <sup>53</sup> 1995	51	IUGR and abnormal umbilical artery Doppler	100 mg	Placebo	28–36
Schiff et al, <sup>58</sup> 1989	65	History risk factors <sup>a</sup> with positive roll-over test	100 mg	Placebo	28–29
Trudinger et al, <sup>62</sup> 1988	46	Abnormal umbilical artery Doppler	150 mg	Placebo	28–36
Yu et al, <sup>68</sup> 2003	554	Abnormal uterine artery Doppler	150 mg	Placebo	22–24

FGR, fetal growth restriction; HTN, hypertension; IUGR, intrauterine growth restriction; MAP, mean arterial pressure; PCOS, polycystic ovary syndrome; PE, preeclampsia.

<sup>a</sup> Includes history of chronic HTN, cardiovascular or endocrine disease, pregnancy HTN, or fetal growth restriction; <sup>b</sup> Studies provided additional information on request; <sup>c</sup> With dipyridamole 150–300 mg daily.

Roberge. Aspirin's dose for prevention of preeclampsia. *Am J Obstet Gynecol* 2017.

Consequently, several national societies are now recommending that women identified as being at high risk for PE should receive low-dose aspirin starting from <16 weeks' gestation.<sup>7-10</sup> The

recommended dose of aspirin varies between 60-150 mg daily but the optimal dose remains unclear. Observational studies suggested that 60-80 mg could be insufficient in some women and that

100-160 mg may be necessary to optimize prevention of PE.<sup>11-14</sup>

The objective of this study is to evaluate the dose-response effect of aspirin for the prevention of PE and FGR.

## Materials and Methods

We performed a systematic review and meta-analysis of RCTs that evaluated the impact of aspirin during pregnancy. Relevant trials were identified through a search of Embase, MEDLINE, the Cochrane Central Register of Controlled Trials, and the Web of Science databases including studies reported from January 1985 through December 2015. We used a combination of key words and Medical Subject Headings terms: “aspirin,” “antiplatelet,” “acetylsalicylic acid,” “ASA,” “pregnancy-complication,” “pregnancy,” “preeclampsia,” “pre-eclampsia,” “hypertension,” “blood pressure,” “eclampsia,” “PIH,” and “toxemia.” No language restriction was imposed. A first reviewer selected all the citations requiring a detailed evaluation. Two independent reviewers selected relevant abstracts and citations for complete evaluation. References of other systematic reviews were also searched for additional studies. In case of missing data in a relevant article, the corresponding and/or the primary authors were contacted for additional information (outcomes and data stratified according to gestational age at randomization). The quality of this review was validated with the preferred reporting items for systematic reviews and meta-analyses tool.<sup>15</sup>


Trials involving pregnant women randomized to either aspirin with or without dipyridamole or to placebo or no treatment were included. Studies using other treatment, other study design, using the same population, or in which relevant data could not be extracted were excluded. Studies were stratified by gestational age at entry based on previous publications ( $\leq 16$  vs  $> 16$  weeks' gestation). The quality of studies was evaluated using the Cochrane handbook criteria for judging risk of bias and a sensitivity analysis was performed to evaluate the effect excluding: (1) studies at high risk of bias; (2) studies with low risk of PE ( $< 7\%$  prevalence in control group); and (3) excluding studies using dipyridamole.<sup>16-18</sup>

Outcomes of interest included PE, usually defined as a systolic blood


**FIGURE 2**

### Assessment of risk of bias in studies included following Cochrane handbook

#### A $\leq 16$ weeks



#### B $> 16$ weeks




Aspirin initiated **A**,  $\leq 16$  weeks and **B**,  $> 16$  weeks of gestation.

Roberge. Aspirin's dose for prevention of preeclampsia. *Am J Obstet Gynecol* 2017.

pressure  $\geq 140$  mm Hg or diastolic blood pressure  $\geq 90$  mm Hg that occurs  $> 20$  weeks' gestation in combination with proteinuria, defined as urinary excretion  $\geq 300$  mg protein in a 24-hour urine specimen or  $\geq 1+$  protein on dipstick.<sup>19</sup> Secondary outcomes included severe PE (any definition) and FGR, defined as birthweight  $< 10$ th or  $< 5$ th percentile for gestational age or similar definition.

Relative risks (RR) were calculated for each study and pooled for global analysis using DerSimonian and Laird random effect to take into account variability and heterogeneity between studies. Heterogeneity between studies was calculated

using Higgins  $I^2$  and considered high if  $\geq 50\%$ .<sup>20,21</sup> Random-effects meta-regression, weighted by the size of the studies, was performed to evaluate the dose-response effect of aspirin. An adjusted  $R^2$  (considering the degree of freedom) coefficient and its  $P$  value were reported for each outcome. The adjusted  $R^2$  represents the proportion of the variance in the dependent variable (in this case, the RR of the disease) that is predictable from the independent variable (dose of aspirin). An adjusted  $R^2$  of 0% or a negative value (reported as 0%) indicates that the variance around the mean cannot be explained by the aspirin

**FIGURE 3****Evaluation of aspirin's dose-response effect when initiated at or before 16 weeks or after 16 weeks of gestation**

Bubble plots with fitted meta-regression line that report relationship between aspirin dosage and relative risks for each adverse pregnancy, according to gestational age at initiation of aspirin.

Roberge. Aspirin's dose for prevention of preeclampsia. *Am J Obstet Gynecol* 2017.

dose, while an adjusted  $R^2$  of 100% indicates that the dose of aspirin could explain the entire variability between the studies.<sup>22</sup> Publication bias was evaluated using funnel plots and symmetry using Egger test, for which a  $P$  value  $<.1$  was considered asymmetrical.<sup>23</sup>

Statistical analysis was performed using Review Manager 5.0.25 software (Nordic Cochrane Center, Cochrane Collaboration, Copenhagen, Denmark), Stata release 14.0 (StataCorp, College Station, TX), and SAS 9.2 software (SAS Institute Inc, Cary, NC).

## Results

The literature search identified 6838 potential citations including 53 studies that met the inclusion criteria. Data stratified according to gestational age were available for 45 studies

that enrolled 20,909 participants (Figure 1).<sup>24-70</sup> The characteristics of each study are reported in Table 1.

### Aspirin initiated at ≤16 weeks' gestation

Data for 5130 participants randomized at ≤16 weeks' gestation were available from 21 studies. The dose of aspirin varied between 50-150 mg daily, including 2 studies that combined 300 mg of dipyridamole with aspirin. In 7 RCTs, a placebo was not used and participants allocated to the control group received no treatment. The risk of bias tool described most studies as being at low or unclear risk of bias (Figure 2, A).

Aspirin was associated with a significant reduction in the prevalence of PE, severe PE, and FGR with a significant

dose-response relationship (Figure 3, Table 2, Supplemental Figures 1, 2, and 3). As a secondary analysis, we compared the 2 most studied dosages (60 mg daily: 4 RCTs,  $n = 3326$ ; and 100 mg daily: 7 RCTs,  $n = 985$ ); aspirin 100 mg vs 60 mg was significantly more effective in reduction of PE (RR, 0.48; 95% confidence interval [CI], 0.31–0.74 vs RR, 0.93; 95% CI, 0.75–1.15;  $P < .001$ ); severe PE (RR, 0.24; 95% CI, 0.09–0.65 vs RR, 0.96; 95% CI, 0.71–1.28;  $P = .002$ ), and FGR (RR, 0.45; 95% CI, 0.28–0.71 vs RR, 0.78; 95% CI, 0.53–1.16;  $P = .006$ ).

Sensitivity analysis revealed a similar dose-response relationship of aspirin initiated at ≤16 weeks for the prevention of PE in high-quality studies (15 studies,  $R^2$ , 100%;  $P = .004$ ), but the association was marginally significant in the subgroup of studies that did not use dipyridamole (16 studies,  $R^2$ , 41%;  $P = .06$ ) and in the subgroup of studies that included high-risk populations (defined as a rate of PE  $>7\%$  in the control group; 17 studies,  $R^2$ , 36%;  $P = .06$ ). The number of studies that randomized women at low risk of PE was too low to evaluate the dose-response effect.

### Aspirin initiated at >16 weeks' gestation

Data for 15,779 participants randomized at >16 weeks' gestation were available from 27 studies. The dose of aspirin varied between 50-150 mg daily. In 2 RCTs, a placebo was not used and participants allocated to the control group received no treatment. The risk of bias tool described most studies as being at low or unclear risk of bias (Figure 2, B).

Aspirin started at >16 weeks was associated with a significant reduction in the prevalence of PE, but there was no dose-response relationship and there was no significant effect on the prevalence of severe PE or FGR (Table 3, Supplemental Figures 4, 5, and 6).

Analysis of the funnel plots suggest the possibility of publication bias because small studies with no beneficial effect were missing (Figure 4).<sup>71</sup> Moreover Egger test suggest asymmetry of the funnel plots: aspirin ≤16

**TABLE 2**  
**Perinatal outcomes  $\leq 16$  weeks according to dose of aspirin at initiation of intervention**

Outcome $\leq 16$ wk	No. of trials	No. of participants	Relative risk (95% confidence interval) random effect	P value	I <sup>2</sup>	Dose-response correlation	
						Adjusted R <sup>2</sup>	P value
<b>Preeclampsia</b>							
50 mg	1	66	0.33 (0.04–3.04)	.33	n/a	44%	.036
60 mg	4	3326	0.93 (0.75–1.15)	.49	0%		
75 mg	2	373	0.42 (0.25–0.70)	.001	72%		
80 mg	4	270	0.52 (0.26–1.01)	.06	1%		
100 mg	7	985	0.48 (0.31–0.74)	.0009	0%		
150 mg	1	93	0.07 (0.00–1.25)	.07	n/a		
Total	19	5113	0.57 (0.43–0.75)	<.001	52%		
<b>Severe preeclampsia</b>							
60 mg	3	3279	0.96 (0.71–1.28)	.77	0%	100%	.008
75 mg	2	373	0.24 (0.09–0.65)	.005	9%		
100 mg	3	334	0.23 (0.08–0.64)	.005	0%		
150 mg	1	93	0.07 (0.00–1.25)	.07	n/a		
Total	9	4079	0.47 (0.26–0.83)	.009	60%		
<b>Fetal growth restriction</b>							
50 mg	1	46	1.00 (0.22–4.45)	1.00	n/a	100%	.044
60 mg	3	1378	0.78 (0.53–1.16)	.22	0%		
75 mg	2	373	0.48 (0.32–0.72)	.0004	0%		
80 mg	3	180	0.64 (0.11–3.74)	.62	0%		
100 mg	7	869	0.45 (0.28–0.71)	.0007	0%		
150 mg	1	93	0.29 (0.10–0.82)	.02	n/a		
Total	17	2939	0.56 (0.44–0.70)	<.001	0%		

n/a, not applicable.

Roberge. Aspirin's dose for prevention of preeclampsia. *Am J Obstet Gynecol* 2017.

weeks:  $P$  value = .091; aspirin  $>16$  weeks:  $P$  value = .007.

## Comment

### Main findings

This meta-analysis demonstrates that the beneficial effect of prophylactic aspirin for the prevention of PE, severe PE, and FGR is conditional on the onset of treatment being at  $\leq 16$  weeks' gestation and has a dose-response effect. The actual evidence shows that 60 mg of aspirin initiated at any time during pregnancy has no impact on the risk of PE, severe PE, and FGR.

The exact mechanism by which aspirin acts to prevent PE and FGR remains unclear. However, the finding

that therapy is effective only when treatment is initiated at  $\leq 16$  weeks is compatible with the knowledge that certainly severe PE, preterm PE, and FGR are associated with impaired placentation; in normal pregnancies the physiological transformation of uterine spiral arteries is completed by 16-18 weeks' gestation.<sup>72-76</sup> We hypothesized that aspirin started  $\leq 16$  weeks can reduce deep placentation disorders in women at high risk of poor placentation and therefore reduce the early and severe forms of PE as well as FGR. However, few studies evaluated the impact of aspirin initiated in early pregnancy on placentation. On the other hand, term and mild PE are likely to be the consequences of

other pathologic processes that can also lead to the maternal syndrome.<sup>77,78</sup> The optimal approaches for the prediction and prevention of the preterm and severe forms of PE are likely to be different than those for the term and mild forms of the disease. As for the need of a minimum dose of aspirin, previous observational studies reported that in a high proportion of women a dose of  $<100$  mg/d is not sufficient to affect platelet function or reduce PE.<sup>11-14</sup>

The clinical impact of such finding is important because maternal history and characteristics, maternal nutritional status, as well as several ultrasound and biochemical markers can identify women who will develop PE, severe PE,

**TABLE 3**  
**Perinatal outcomes >16 weeks according to dose of aspirin at initiation of intervention**

Outcome >16 wk	No. of trials	No. of participants	Relative risk (95% confidence interval) random effect	P value	I <sup>2</sup>	Dose response	
						Adjusted R <sup>2</sup>	P value
<b>Preeclampsia</b>							
50 mg	1	26	2.00 (0.44–9.08)	.37	n/a	0%	.941
60 mg	8	12,274	0.88 (0.68–1.12)	.30	57%		
75 mg	4	1933	0.69 (0.42–1.15)	.16	20%		
80 mg	2	234	0.21 (0.06–0.70)	.01	0%		
100 mg	5	349	0.61 (0.26–1.44)	.26	52%		
150 mg	1	554	0.95 (0.67–1.35)	.77	n/a		
Total	21	15,370	0.81 (0.66–0.99)	.04	48%		
<b>Severe preeclampsia</b>							
60 mg	6	9358	0.87 (0.60–1.25)	.45	58%	0%	.838
75 mg	1	118	0.34 (0.01–8.29)	.51	n/a		
80 mg	1	41	0.17 (0.01–3.41)	.25	n/a		
100 mg	1	65	0.46 (0.04–4.78)	.51	n/a		
150 mg	1	554	0.82 (0.44–1.51)	.52	n/a		
Total	10	10,136	0.85 (0.64–1.14)	.28	37%		
<b>Fetal growth restriction</b>							
50 mg	1	26	2.00 (0.21–19.44)	.55	n/a	n/a	.563
60 mg	7	7438	0.96 (0.78–1.17)	.67	13%		
75 mg	4	538	0.82 (0.49–1.38)	.46	26%		
80 mg	1	41	0.43 (0.04–4.40)	.48	n/a		
100 mg	4	325	0.96 (0.84–1.11)	.59	0%		
150 mg	1	554	0.90 (0.67–1.22)	.51	n/a		
Total	18	8922	0.95 (0.86–1.05)	.34	0%		

n/a, not applicable because there were not enough permutations for this statistical comparison.

Roberge. Aspirin's dose for prevention of preeclampsia. *Am J Obstet Gynecol* 2017.

early-onset PE, and FGR before the first symptoms, and as early as the first trimester of pregnancy.<sup>79-96</sup> Combined screening by maternal factors, uterine artery pulsatility index, mean arterial pressure, and placental growth factor in the first trimester has been associated with a detection rate of 75% of preterm PE and 47% of PE at a false-positive rate of 10%.<sup>97</sup> This growing body of evidences suggests that preterm PE and FGR can be predicted in early pregnancy and prevented with a minimum dose of aspirin initiated also in early pregnancy.<sup>98,99</sup> The Aspirin for Evidence-Based Preeclampsia Prevention Trial is evaluating the impact of aspirin at 150 mg daily started at the end of the first

trimester for the prevention of preterm PE in women identified at high risk of preterm PE using such combined screening.<sup>100</sup>

#### Comparison with previous studies


The finding that low-dose aspirin started at ≤16 weeks in high-risk women reduces the prevalence of PE and FGR is in agreement with that of previous meta-analyses.<sup>5,6,101,102</sup> Similarly, the finding that the effectiveness of aspirin is not only dependent on the gestational age at initiation of treatment but also on the dose of the drug is supported by the results of a previous meta-analysis, from the Cochrane Database, which reported a greater reduction in the risk of PE with

the use of aspirin >75 mg/d (17 trials; N = 3061; RR, 0.64; 95% CI, 0.51–0.80) or the combination of aspirin >75 mg/d and dipyridamole (5 trials; N = 506; RR, 0.30; 95% CI, 0.15–0.60) compared to aspirin ≤75 mg/d (21 trials; N = 26,984; RR, 0.88; 95% CI, 0.81–0.95).<sup>103</sup> Another meta-analysis (13 trials; N = 13,234) reported that the effect of aspirin for the prevention of FGR was greater when treatment started at ≤16 weeks' gestation and the dose was 100-150 mg/d rather than 50-80 mg/d.<sup>104</sup>

#### Limitations

The main limitation of this meta-analysis is the absence of large RCTs that recruited all participants in early

**FIGURE 4**  
**Funnel plot of trials for preeclampsia**



Aspirin initiated **A**,  $\leq 16$  weeks and **B**,  $> 16$  weeks of gestation.

Roberge. Aspirin's dose for prevention of preeclampsia. *Am J Obstet Gynecol* 2017.

pregnancy and more specifically  $\leq 16$  weeks of gestation. Most data from participants recruited at  $\leq 16$  weeks' gestation come from small to moderate RCTs or from subgroups of participants recruited in larger RCTs. It could be argued that the use of subgroups (several dosages, several gestational ages) and multiple analyses could lead to potential biases.<sup>105</sup> An additional limitation is that we are unable to determine the optimal dose of aspirin based on this meta-regression analysis,

as the number of participants per subgroups is too small, and there is unexplained heterogeneity in some subgroup. Two dosages (60 and 100 mg/d) were studied in sufficient depth to allow direct comparison. Data from large, high-quality trials show that 60 mg/d has no significant impact on the prevalence of PE, severe PE, or FGR. In contrast, all of these outcomes were associated with a significant reduction in prevalence when 100 mg/d was started at  $\leq 16$  weeks' gestation.

## Conclusions

The results of this meta-analysis suggest that in high-risk women the effect of aspirin for the prevention of PE, severe PE, and FGR is dose-dependent and optimal when initiated  $\leq 16$  weeks of gestation. ■

## REFERENCES

1. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. *Lancet* 2010;376:631-44.
2. Toohar J, Thornton C, Makris A, et al. Hypertension in pregnancy and long-term cardiovascular mortality: a retrospective cohort study. *Am J Obstet Gynecol* 2016;214:722.e1-6.
3. Lo JO, Mission JF, Caughey AB. Hypertensive disease of pregnancy and maternal mortality. *Curr Opin Obstet Gynecol* 2013;25:124-32.
4. Lewandowski AJ, Leeson P. Preeclampsia, prematurity and cardiovascular health in adult life. *Early Hum Dev* 2014;90:725-9.
5. Roberge S, Nicolaides KH, Demers S, Villa P, Bujold E. Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. *Ultrasound Obstet Gynecol* 2013;41:491-9.
6. Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. *Obstet Gynecol* 2010;116:402-14.
7. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P; Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. *J Obstet Gynaecol Can* 2014;36:416-41.
8. American Congress of Obstetricians and Gynecologists. Hypertension in Pregnancy. Available at: <http://www.acog.org/Resources-And-Publications/Task-Force-and-Work-Group-Reports/Hypertension-in-Pregnancy>. Accessed November 30, 2016.
9. Henderson JT, Whitlock EP, O'Connor E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the US Preventive Services Task Force. *Ann Intern Med* 2014;160:695-703.
10. NICE Clinical Guideline. National Collaborating Center for Women's and Children's Health. Commissioned by the National Institute for Health and Clinical Excellence. Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. Available at: <http://guidance.nice.org.uk/CG107>. Accessed April 17, 2014.
11. Caron N, Rivard GE, Michon N, et al. Low-dose ASA response using the PFA-100 in women with high-risk pregnancy. *J Obstet Gynaecol Can* 2009;31:1022-7.



12. Wojtowicz A, Undas A, Huras H, et al. Aspirin resistance may be associated with adverse pregnancy outcomes. *Neuro Endocrinol Lett* 2011;32:334-9.
13. Dumont A, Flahault A, Beauflis M, Verdy E, Uzan S. Effect of aspirin in pregnant women is dependent on increase in bleeding time. *Am J Obstet Gynecol* 1999;180:135-40.
14. Rey E, Rivard GE. Is testing for aspirin response worthwhile in high-risk pregnancy? *Eur J Obstet Gynecol Reprod Biol* 2011;157:38-42.
15. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6:e1000097.
16. Higgins J, Green S, eds. *Cochrane handbook for systematic reviews of interventions*. Cochrane Collaboration; 2011. Available at: <http://handbook.cochrane.org>. Accessed November 30, 2016.
17. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *JAMA* 1995;273:408-12.
18. Rey E, Derderian F. Efficacité de l'aspirine à faible dose au cours de la grossesse en fonction des facteurs de risque maternels et foetaux. *J Obstet Gynaecol Can* 1996;18:51-60.
19. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. *Obstet Gynecol* 2013;122:1122-31.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557-60.
21. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I<sup>2</sup> index? *Psychol Methods* 2006;11:193-206.
22. Harbord R, Higgins J. Meta-regression in Stata. *Stata J* 2008;8:493-519.
23. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629-34.
24. CLASP. A randomized trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. *Lancet* 1994;343:619-29.
25. ECPPA. Randomized trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. ECPPA (Estudo Colaborativo para Prevencao da Pre-eclampsia com Aspirina) Collaborative Group. *Br J Obstet Gynaecol* 1996;103:39-47.
26. August P, Helseth G, Edersheim T, Hutson J, Druzin M. Sustained release, low-dose aspirin ameliorates but does not prevent preeclampsia (PE) in a high risk population. Proceedings of 9th International Congress, International Society for the Study of Hypertension. Sydney (Australia): Hypertension in Pregnancy; 1994. p.72.
27. Ayala DE, Ucieda R, Hermida RC. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. *Chronobiol Int* 2013;30:260-79.
28. Azar R, Turpin D. Effect of antiplatelet therapy in women at high risk for pregnancy-induced hypertension. Proceedings of 7th World Congress of Hypertension in Pregnancy. Perugia (Italy); 1990:257.
29. Bakhti A, Vaiman D. Prevention of gravidic endothelial hypertension by aspirin treatment administered from the 8th week of gestation. *Hypertens Res* 2011;34:1116-20.
30. Bakhti A, Vaiman D. Prevention of gravidic endothelial hypertension by aspirin treatment administered from the 8th week of gestation. *Hypertens Res* 2012;35:244.
31. Beauflis M, Uzan S, Donsimoni R, Colau JC. Prevention of pre-eclampsia by early antiplatelet therapy. *Lancet* 1985;1:840-2.
32. Benigni A, Gregorini G, Frusca T, et al. Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. *N Engl J Med* 1989;321:357-62.
33. Byaruhanga RN, Chipato T, Rusakaniko S. A randomized controlled trial of low-dose aspirin in women at risk from pre-eclampsia. *Int J Gynaecol Obstet* 1998;60:129-35.
34. Caritis S, Sibai B, Hauth J, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. *N Engl J Med* 1998;338:701-5.
35. Chiapparino F, Parazzini F, Paladini D, et al. A small randomized trial of low-dose aspirin in women at high risk of pre-eclampsia. *Eur J Obstet Gynecol Reprod Biol* 2004;112:142-4.
36. Dasari R, Narang A, Vasishtha K, Garewal G. Effect of maternal low dose aspirin on neonatal platelet function. *Indian Pediatr* 1998;35:507-11.
37. Davies N, Gazvani M, Farquharson R, Walkinshaw S. Low-dose aspirin in the prevention of hypertensive disorders of pregnancy in relatively low-risk nulliparous women. *Hypertens Pregnancy* 1995;14:49-55.
38. Ebrashy A, Ibrahim M, Marzook A, Yousef D. Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery Doppler ultrasound at 14-16 weeks pregnancy: randomized controlled clinical trial. *Croat Med J* 2005;46:826-31.
39. Ferrier C, North R, Kincaid-Smith P. Low dose aspirin delays the onset of pre-eclampsia in pregnancies with abnormal uteroplacental circulation. Proceedings of the 10th World Congress of the International Society for the Study of Hypertension in Pregnancy. Seattle (Washington); 1996:151.
40. Gallery E, Ross M, Hawkins M, Leslie G, Gyory A. Low-dose aspirin in high-risk pregnancy. *Hypertens Pregnancy* 1997;16:229-38.
41. Golding J. A randomized trial of low dose aspirin for primiparae in pregnancy. *The Jamaica Low Dose Aspirin Study Group. Br J Obstet Gynaecol* 1998;105:293-9.
42. Grab D, Paulus WE, Erdmann M, et al. Effects of low-dose aspirin on uterine and fetal blood flow during pregnancy: results of a randomized, placebo-controlled, double-blind trial. *Ultrasound Obstet Gynecol* 2000;15:19-27.
43. Hauth JC, Goldenberg RL, Parker CR Jr, et al. Low-dose aspirin therapy to prevent pre-eclampsia. *Am J Obstet Gynecol* 1993;168:1083-91.
44. Hermida RC, Ayala DE, Fernandez JR, et al. Administration time-dependent effects of aspirin in women at differing risk for preeclampsia. *Hypertension* 1999;34:1016-23.
45. Hermida RC, Ayala DE, Iglesias M, et al. Time-dependent effects of low-dose aspirin administration on blood pressure in pregnant women. *Hypertension* 1997;30:589-95.
46. Jamal A, Milani F, Al-Yasin A. Evaluation of the effect of metformin and aspirin on utero placental circulation of pregnant women with PCOS. *Iran J Reprod Med* 2012;10:265-70.
47. Kim HS, Kim KS, Kim TY, Cho JS, Park YW, Song CH. Clinical efficacy of Doppler ultrasound for low dose aspirin therapy in high risk pregnancy. *Korean J Obstet Gynecol* 1997;40:71-7.
48. McCowan LM, Harding J, Roberts A, Barker S, Ford C, Stewart A. Administration of low-dose aspirin to mothers with small for gestational age fetuses and abnormal umbilical Doppler studies to increase birthweight: a randomized double-blind controlled trial. *Br J Obstet Gynaecol* 1999;106:647-51.
49. McParland P, Pearce JM, Chamberlain GV. Doppler ultrasound and aspirin in recognition and prevention of pregnancy-induced hypertension. *Lancet* 1990;335:1552-5.
50. Mesdaghinia E, Talari H, Abedzadeh-Kalahroudi M. Effect of aspirin for prevention of preeclampsia in women with abnormal ultrasonic findings in uterine artery. *Feyz* 2011;15:98-104.
51. Michael C, Walters B. Low-dose aspirin in the prevention of pre-eclampsia: current evaluation. In: Teoh ES, Ratnam SS, Macnaughton MC, eds. *Maternal physiology and pathology. The current status of gynecology and obstetrics series*. Carnforth (United Kingdom): Parthenon Publishing Group Ltd; 1992:183-9.
52. Morris J, Fay R, Ellwood D, Cook CM, Devonald KJ. A randomized controlled trial of aspirin in patients with abnormal uterine artery blood flow. *Obstet Gynecol* 1996;87:74-8.
53. Newnham J, Godfrey M, Walters B, Philips J, Evans S. Low dose aspirin for the treatment of fetal growth restriction: a randomized controlled trial. *Aust N Z J Obstet Gynaecol* 1995;35:370-4.
54. Odibo AO, Goetzinger KR, Odibo L, Tuuli MG. Early prediction and aspirin for prevention of pre-eclampsia (EPAPP) study: a randomized controlled trial. *Ultrasound Obstet Gynecol* 2015;46:414-8.

55. Omrani GR, Karimi MM, Zareh F. Prevention of pregnancy-induced hypertension by low dose aspirin. *Iran J Med Sci* 1992;17:131-6.
56. Porreco RP, Hickok DE, Williams MA, Krenning C. Low-dose aspirin and hypertension in pregnancy. *Lancet* 1993;341:312.
57. Rotchell YE, Cruickshank JK, Gay MP, et al. Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomized trial for the prevention of pre-eclampsia and its complications. *Br J Obstet Gynaecol* 1998;105:286-92.
58. Schiff E, Peleg E, Goldenberg M, et al. The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. *N Engl J Med* 1989;321:351-6.
59. Schrocksnadel H, Sitte B, Alge A, et al. Low-dose aspirin in primigravidae with positive rollover test. *Gynecol Obstet Invest* 1992;34:146-50.
60. Sibai BM, Caritis SN, Thom E, et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. *N Engl J Med* 1993;329:1213-8.
61. Talari H, Mesdaghinia E, Abedzadeh Kalahroudi M. Aspirin and preeclampsia prevention in patients with abnormal uterine artery blood flow. *Iran Red Crescent Med J* 2014;16:e17175.
62. Trudinger B, Cook C, Thompson R, Giles W, Connelly A. Low-dose aspirin therapy improves fetal weight in umbilical placental insufficiency. *Am J Obstet Gynecol* 1988;159:681-5.
63. Tulppala M, Marttunen M, Soderstrom-Anttila V, et al. Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production. *Hum Reprod* 1997;12:1567-72.
64. Villa PM, Kajantie E, Raikonen K, et al. Aspirin in the prevention of pre-eclampsia in high-risk women: a randomized placebo-controlled PREDO trial and a meta-analysis of randomized trials. *BJOG* 2013;120:64-74.
65. Wallenburg HC, Dekker GA, Makovitz JW, Rotmans N. Effect of low-dose aspirin on vascular refractoriness in angiotensin-sensitive primigravid women. *Am J Obstet Gynecol* 1991;164:1169-73.
66. Wallenburg HC, Dekker GA, Makovitz JW, Rotmans P. Low-dose aspirin prevents pregnancy-induced hypertension and preeclampsia in angiotensin-sensitive primigravidae. *Lancet* 1986;1:1-3.
67. Wang Z, Li W. A prospective randomized placebo-controlled trial of low-dose aspirin for prevention of intra-uterine growth retardation. *Chin Med J (Engl)* 1996;109:238-42.
68. Yu CK, Papageorgiou AT, Parra M, Palma Dias R, Nicolaides KH. Randomized controlled trial using low-dose aspirin in the prevention of pre-eclampsia in women with abnormal uterine artery Doppler at 23 weeks' gestation. *Ultrasound Obstet Gynecol* 2003;22:233-9.
69. Zhao Y-M, Xiao L-P, Hu H, Yang X-N, Xu Y-Q, Guo L-M. Low-dose aspirin prescribed at bed time for the prevention of preeclampsia in high-risk pregnant women. *Reprod Contracept* 2012;32:355-9.
70. Zimmermann P, Eirio V, Koskinen J, et al. Effect of low dose aspirin treatment on vascular resistance in the uterine, uteroplacental, renal and umbilical arteries—a prospective longitudinal study on a high risk population with persistent notch in the uterine arteries. *Eur J Ultrasound* 1997;5:17-30.
71. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. *BMJ* 2001;323:101-5.
72. Fisher SJ. Why is placentation abnormal in preeclampsia? *Am J Obstet Gynecol* 2015;213:S115-22.
73. Ogge G, Chaiworapongsa T, Romero R, et al. Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia. *J Perinat Med* 2011;39:641-52.
74. Pijnenborg R, Dixon G, Robertson WB, Brosens I. Trophoblastic invasion of human decidua from 8 to 18 weeks of pregnancy. *Placenta* 1980;1:3-19.
75. De Wolf F, De Wolf-Peeters C, Brosens I, Robertson WB. The human placental bed: electron microscopic study of trophoblastic invasion of spiral arteries. *Am J Obstet Gynecol* 1980;137:58-70.
76. Brosens I, Pijnenborg R, Vercruyse L, Romero R. The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. *Am J Obstet Gynecol* 2011;204:193-201.
77. Redman CW, Staff AC. Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity. *Am J Obstet Gynecol* 2015;213:S9.e1-11.
78. Soto E, Romero R, Kusanovic JP, et al. Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. *J Matern Fetal Neonatal Med* 2012;25:498-507.
79. Demers S, Bujold E, Arenas E, Castro A, Nicolaides KH. Prediction of recurrent preeclampsia using first-trimester uterine artery Doppler. *Am J Perinatol* 2014;31:99-104.
80. Effendi M, Demers S, Giguere Y, et al. Association between first-trimester placental volume and birth weight. *Placenta* 2014;35:99-102.
81. Forest JC, Theriault S, Masse J, Bujold E, Giguere Y. Soluble Fms-like tyrosine kinase-1 to placental growth factor ratio in mid-pregnancy as a predictor of preterm preeclampsia in asymptomatic pregnant women. *Clin Chem Lab Med* 2014;52:1169-78.
82. Demers S, Girard M, Roberge S, et al. First-trimester placental and myometrial blood perfusion measured by three-dimensional power Doppler in preeclampsia. *Am J Perinatol* 2015;32:920-6.
83. Tancrede S, Bujold E, Giguere Y, Renald MH, Girouard J, Forest JC. Mid-trimester maternal serum AFP and hCG as markers of preterm and term adverse pregnancy outcomes. *J Obstet Gynaecol Can* 2015;37:111-6.
84. Lesmes C, Gallo DM, Saiid Y, Poon LC, Nicolaides KH. Prediction of small-for-gestational-age neonates: screening by uterine artery Doppler and mean arterial pressure at 19-24 weeks. *Ultrasound Obstet Gynecol* 2015;46:332-40.
85. Poon LC, Lesmes C, Gallo DM, Akolekar R, Nicolaides KH. Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 19-24 weeks. *Ultrasound Obstet Gynecol* 2015;46:437-45.
86. Cohen JM, Kramer MS, Platt RW, Basso O, Evans RW, Kahn SR. The association between maternal antioxidant levels in midpregnancy and preeclampsia. *Am J Obstet Gynecol* 2015;213:695.e1-13.
87. Bahado-Singh RO, Syngelaki A, Akolekar R, et al. Validation of metabolomic models for prediction of early-onset preeclampsia. *Am J Obstet Gynecol* 2015;213:530.e1-10.
88. Wright D, Syngelaki A, Akolekar R, Poon LC, Nicolaides KH. Competing risks model in screening for preeclampsia by maternal characteristics and medical history. *Am J Obstet Gynecol* 2015;213:62.e1-10.
89. van Oostwaard MF, Langenveld J, Schuit E, et al. Recurrence of hypertensive disorders of pregnancy: an individual patient data meta-analysis. *Am J Obstet Gynecol* 2015;212:624.e1-17.
90. Achkar M, Dodds L, Giguere Y, et al. Vitamin D status in early pregnancy and risk of preeclampsia. *Am J Obstet Gynecol* 2015;212:511.e1-7.
91. Sween LK, Althouse AD, Roberts JM. Early-pregnancy percent body fat in relation to preeclampsia risk in obese women. *Am J Obstet Gynecol* 2015;212:84.e1-7.
92. Metz TD, Allshouse AA, Euser AG, Heyborne KD. Preeclampsia in high risk women is characterized by risk group-specific abnormalities in serum biomarkers. *Am J Obstet Gynecol* 2014;211:512.e1-6.
93. Baschat AA, Magder LS, Doyle LE, Atlas RO, Jenkins CB, Blitzer MG. Prediction of preeclampsia utilizing the first trimester screening examination. *Am J Obstet Gynecol* 2014;211:514.e1-7.
94. Schneuer FJ, Roberts CL, Ashton AW, et al. Angiotensin 1 and 2 serum concentrations in first trimester of pregnancy as biomarkers of adverse pregnancy outcomes. *Am J Obstet Gynecol* 2014;210:345.e1-9.
95. Bigelow CA, Pereira GA, Warnsley A, et al. Risk factors for new-onset late postpartum preeclampsia in women without a history of preeclampsia. *Am J Obstet Gynecol* 2014;210:338.e1-8.
96. Tache V, Baer RJ, Currier RJ, et al. Population-based biomarker screening and

the development of severe preeclampsia in California. *Am J Obstet Gynecol* 2014;211:377.e1-8.

**97.** O'Gorman N, Wright D, Syngelaki A, et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. *Am J Obstet Gynecol* 2016;214:103.e1-12.

**98.** Wright D, Akolekar R, Syngelaki A, Poon LC, Nicolaides KH. A competing risks model in early screening for preeclampsia. *Fetal Diagn Ther* 2012;32:171-8.

**99.** Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH. Combined screening for preeclampsia and small for gestational age at 11-13 weeks. *Fetal Diagn Ther* 2013;33:16-27.

**100.** O'Gorman N, Wright D, Rolnik DL, Nicolaides KH, Poon LC. Study protocol for the randomized controlled trial: combined multi-marker screening and randomized patient treatment with ASpirin for evidence-based PREEclampsia prevention (ASPRE). *BMJ Open* 2016;6:e011801.

**101.** Roberge S, Giguere Y, Villa P, et al. Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. *Am J Perinatol* 2012;29:551-6.

**102.** Roberge S, Villa P, Nicolaides K, et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. *Fetal Diagn Ther* 2012;31:141-6.

**103.** Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing preeclampsia and its complications. *Cochrane Database Syst Rev* 2007;2:CD004659.


**104.** Leitch H, Egarter C, Husslein P, Kaidler A, Schemper M. A meta-analysis of low dose aspirin for the prevention of intrauterine growth retardation. *Br J Obstet Gynaecol* 1997;104:450-9.

**105.** Rothwell PM. Treating individuals 2. Subgroup analysis in randomized controlled trials: importance, indications, and interpretation. *Lancet* 2005;365:176-86.

**106.** Rogers MS, Fung HY. Calcium and low-dose aspirin prophylaxis in women at high risk of pregnancy-induced hypertension. *Hypertens Pregnancy* 18:165-72.

## SUPPLEMENTAL FIGURE 1

## Forest plot of effect of low-dose aspirin on risk of preeclampsia 16 weeks, subgrouped by aspirin dose




CI, confidence interval; M-H, Mantel-Haenszel.

Roberge. Aspirin's dose for prevention of preeclampsia. *Am J Obstet Gynecol* 2017.

**SUPPLEMENTAL FIGURE 2**

**Forest plot of effect of low-dose aspirin on risk of severe preeclampsia 16 weeks, subgrouped by aspirin dose**




CI, confidence interval; M-H, Mantel-Haenszel.

Roberge. Aspirin's dose for prevention of preeclampsia. *Am J Obstet Gynecol* 2017.

## SUPPLEMENTAL FIGURE 3

## Forest plot of effect of low-dose aspirin on risk of fetal growth restriction 16 weeks, subgrouped by aspirin dose




CI, confidence interval; M-H, Mantel-Haenszel.

Roberge. Aspirin's dose for prevention of preeclampsia. *Am J Obstet Gynecol* 2017.

**SUPPLEMENTAL FIGURE 4**

**Forest plot of effect of low-dose aspirin on risk of preeclampsia >16 weeks, subgrouped by aspirin dose**




CI, confidence interval; M-H, Mantel-Haenszel.

Roberge. Aspirin's dose for prevention of preeclampsia. *Am J Obstet Gynecol* 2017.

**SUPPLEMENTAL FIGURE 5**

**Forest plot of effect of low-dose aspirin on risk of severe preeclampsia >16 weeks, subgrouped by aspirin dose**




CI, confidence interval; M-H, Mantel-Haenszel.

Roberge. Aspirin's dose for prevention of preeclampsia. Am J Obstet Gynecol 2017.



**SUPPLEMENTAL FIGURE 6**

**Forest plot of effect of low-dose aspirin on risk of fetal growth restriction >16 weeks, subgrouped by aspirin dose**



CI, confidence interval; M-H, Mantel-Haenszel.

Roberge. Aspirin's dose for prevention of preeclampsia. Am J Obstet Gynecol 2017.